600276: Jiangsu Hengrui Medicine Co., Ltd. - Summary | Jitta

Jiangsu Hengrui Medicine Co., Ltd.

CHN:600276

Price
CN¥32.93
Loss Chance
47.1%
5.23JITTA SCORE
116.86%Over Jitta Line
Jitta Ranking
310 / 448
3,023 / 4,778
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (36)
Recent Business Performance (33)
Financial Strength (88)
Return to Shareholders (59)
Competitive Advantage (53)
Jitta Signs
Revenue and EarningConsistent Growth in the past 5 years
Debt LevelLow Long Term Debt
Dividend PayoutEvery year
Operating MarginDeclined
Recent Business PerformanceEarning decline 28.63% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
5.23
116.86%
4.65
> 1,000%
4.76
> 1,000%
Pharmaceuticals
6.62
11.76%
7.61
13.73%
7.03
5.82%
COMPANY DESCRIPTION
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.